ABSTRACT
The treatment of non-small cell lung cancer (NSCLC) has been undergoing major changes in recent years: increasingly, a multimodality approach is being adopted, applying surgery, radiotherapy, and chemotherapy given either sequentially or concomitantly in selected groups of patients. Also, refinements of currently available treatments continue to take place, although there is a sense that the use of traditional chemotherapeutic agents has reached a therapeutic plateau. Therefore, it is encouraging that recently developed molecular techniques have allowed for a greater understanding of the specific genetic and biologic properties of individual lung cancers which has led to new therapies that target epidermal growth factor receptor (EGFR), protein kinase C and the angiogenesis pathways.
